Sector News

Nestlé to buy Aimmune Therapeutics in $2.6bn deal

September 2, 2020
Food & Drink

Nestlé Health Science has agreed to acquire Aimmune Therapeutics, a peanut allergy treatment maker, in a deal worth approximately $2.6 billion.

Founded in 2011, Aimmune is a biopharmaceutical company which develops and commercialises treatments for patients with food allergies.

The firm claims that its recently approved therapy Palforzia is the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4-17.

With the merger, Nestlé Health Science aims to create a global leader in food allergy prevention and treatment and create a wider offering of solutions for children living with food allergies.

“This transaction brings together Nestlé’s nutritional science leadership with one of the most innovative companies in food allergy treatment. Together we will be able to offer a wide range of solutions that can transform the lives of people suffering from food allergies around the world,” said Nestlé Health Science CEO Greg Behar.

Nestlé Health Science first invested in Aimmune in November 2016, before making additional investments and taking its ownership stake to 25.6% for a total of $473 million.

Under the terms of the agreement, Nestlé’s wholly-owned subsidiary, Société des Produits Nestlé SA, will commence a cash tender offer to acquire all outstanding shares of Aimmune common stock that are not already owned by Nestlé Health Science, representing a total enterprise value of approximately $2.6 billion.

Jayson Dallas, managing director, president and CEO of Aimmune, said: “Delivering Palforzia, the world’s first treatment for food allergy, has been a game-changing proposition in the bio-pharmaceutical industry and is transformative for the lives of millions of people living with potentially life-threatening peanut allergy.

“This acquisition ensures a level of support for Palforzia and our pipeline that will further enhance their potential for patients around the world living with food allergies.”

The deal marks the latest in a series of acquisitions by Nestlé Health Science including IM HealthScience and Vital Proteins, a producer of collagen-based beverages, food products and supplements.

The transaction, which is subject to customary conditions and regulatory approvals, is expected to close in the fourth quarter of 2020.

By: Emma Upshall

Source: Food Bev Media

comments closed

Related News

October 2, 2022

Drinktec 2022: In review

Food & Drink

In the lead-up to the world-famous Oktoberfest – which celebrates Bavarian tradition, beer and the festival spirit – Munich was already buzzing with activity by the time the doors opened to Drinktec 2022 on 12-16 September. The atmosphere was lively, with approximately 50,000 visitors from 169 countries in attendance.

October 2, 2022

Alan Jope to step down as Unilever CEO

Food & Drink

Unilever has announced CEO Alan Jope’s decision to retire from the company at the end of 2023, after five years at the helm. The announcement comes less than a year after a failed attempt by Unilever to buy GlaxoSmithKline’s consumer healthcare business and just months after activist investor Nelson Peltz joined the company’s board.

October 2, 2022

Lakeland Dairies names Colin Kelly as next group CEO

Food & Drink

Lakeland Dairies has announced that Colin Kelly will assume the role of group CEO following the retirement of Michael Hanley at the end of the year. Kelly will take up the position in January 2023, while Hanley will step down in December this year.